Short answer
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Board expanded from 8 to 9 directors with John C. Reed, M.D., Ph.D. joining as a Class II director through 2027.
MADRIGAL PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 8 to 9 directors with John C. Reed, M.D., Ph.D. joining as a Class II director through 2027
- Reed appointed to the Science and Technology Committee, adding senior scientific expertise to oversight
- Annual compensation includes $50,000 cash retainer plus $10,000 committee fee
- Initial equity award valued at $675,000, split evenly between stock options and restricted stock units
- No disclosed related-party interests or selection arrangements, reducing governance conflict concerns
Item 7.01 · Regulation FD Disclosure
- August 12, 2026 press release furnished under Exhibit 99.1
- Exhibit contains the substantive Regulation FD disclosure relevant to investors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MADRIGAL PHARMACEUTICALS, INC. 8-K filings
Get the next MDGL 8-K as it lands
Follow MDGL for push alerts, or ask the research agent what this filing means.